


Healthcare News Roundup: Neuro
HSMN NewsFeed - 23 Dec 2011
MindFrame Inc. Launches Registry to Improve Quality of Care for Patients Experiencing Ischemic Stroke
MindFrame Inc. Launches Registry to Improve Quality of Care for Patients Experiencing Ischemic Stroke
HSMN NewsFeed - 21 Dec 2011
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease
HSMN NewsFeed - 19 Dec 2011
Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
HSMN NewsFeed - 15 Dec 2011
World's First Curve(TM) Image Guided Surgery System Now Operating in Germany
World's First Curve(TM) Image Guided Surgery System Now Operating in Germany
HSMN NewsFeed - 10 Dec 2011
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
HSMN NewsFeed - 8 Dec 2011
X-spine Announces FDA Clearance of New Spinal Implant System for Treatment of Disk Disease
X-spine Announces FDA Clearance of New Spinal Implant System for Treatment of Disk Disease
HSMN NewsFeed - 8 Dec 2011
Spinal Modulation System Receives CE Mark for the Management of Chronic Intractable Pain
Spinal Modulation System Receives CE Mark for the Management of Chronic Intractable Pain
HSMN NewsFeed - 29 Nov 2011
Ascendx Spine(TM) Appoints Pilar Debelius-Kinsey as Sales and Marketing Manager, Europe
Ascendx Spine(TM) Appoints Pilar Debelius-Kinsey as Sales and Marketing Manager, Europe
HSMN NewsFeed - 16 Nov 2011
Alphatec Spine Appoints New Senior Vice President, Global Marketing and Asia Pacific
Alphatec Spine Appoints New Senior Vice President, Global Marketing and Asia Pacific
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
